These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 3082618)

  • 1. Treatment of breast cancer with gonadotropin-releasing hormone.
    Manni A; Santen R; Harvey H; Lipton A; Max D
    Endocr Rev; 1986 Feb; 7(1):89-94. PubMed ID: 3082618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women.
    Filicori M; Flamigni C; Cognigni G; Dellai P; Arnone R; Falbo A; Capelli M
    J Clin Endocrinol Metab; 1993 Jul; 77(1):130-3. PubMed ID: 8325935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer.
    Klijn JG; de Jong FH
    Lancet; 1982 May; 1(8283):1213-6. PubMed ID: 6122975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer.
    Harvey HA; Lipton A; Max DT; Pearlman HG; Diaz-Perches R; de la Garza J
    J Clin Oncol; 1985 Aug; 3(8):1068-72. PubMed ID: 3926958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women.
    Sherman BM; Chapler FK; Crickard K; Wycoff D
    J Clin Invest; 1979 Aug; 64(2):398-404. PubMed ID: 110834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone agonist suppresses ovulation, menses, and endometriosis in monkeys: an individualized, intermittent regimen.
    Werlin LB; Hodgen GD
    J Clin Endocrinol Metab; 1983 Apr; 56(4):844-8. PubMed ID: 6403565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
    Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
    Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients.
    Rose DP; Davis TE
    Cancer Res; 1980 Nov; 40(11):4043-7. PubMed ID: 6451282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.
    Jordan VC; Fritz NF; Tormey DC
    Cancer Res; 1987 Jan; 47(2):624-30. PubMed ID: 3098415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.
    Steingold K; De Ziegler D; Cedars M; Meldrum DR; Lu JK; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1987 Oct; 65(4):773-8. PubMed ID: 3116031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.
    Klijn JG; de Jong FH; Blankenstein MA; Docter R; Alexieva-Figusch J; Blonk-van der Wijst J; Lamberts SW
    Breast Cancer Res Treat; 1984; 4(3):209-20. PubMed ID: 6435703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion.
    Sklar CA; Rothenberg S; Blumberg D; Oberfield SE; Levine LS; David R
    J Clin Endocrinol Metab; 1991 Oct; 73(4):734-8. PubMed ID: 1909701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.
    Klibanski A; Jameson JL; Biller BM; Crowley WF; Zervas NT; Rivier J; Vale WW; Bikkal H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):81-6. PubMed ID: 2535852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma.
    Santen RJ; Demers LM; Max DT; Smith J; Stein BS; Glode LM
    J Clin Endocrinol Metab; 1984 Feb; 58(2):397-400. PubMed ID: 6420439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic use of a gonadotropin releasing hormone analogue in breast cancer].
    Kahán Z; Falkay G
    Orv Hetil; 1990 May; 131(19):1033-6. PubMed ID: 2111904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of hot flashes in premenopausal women treated with a long-acting GnRH agonist.
    DeFazio J; Meldrum DR; Laufer L; Vale W; Rivier J; Lu JK; Judd HL
    J Clin Endocrinol Metab; 1983 Mar; 56(3):445-8. PubMed ID: 6401756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.